Phase I/II Trial of MEK Inhibitor MEK162 in Patients with Relapsed and or Refractory Acute Myeloid Leukemia and Patients with Po
Phase I/II Trial of MEK Inhibitor MEK162 in Patients with Relapsed and or Refractory Acute Myeloid Leukemia and Patients with Po
Phase I/II Trial of MEK Inhibitor MEK162 in Patients with Relapsed and or Refractory Acute Myeloid Leukemia and Patients with Po
![Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity - Carls - 2014 - British Journal of Clinical Pharmacology - Wiley Online Library Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity - Carls - 2014 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/68e200bb-e9dc-4580-87d8-b5d7a3f7b7d0/bcp12497-fig-0003-m.jpg)